Protection when you need it. Patency when you don’t.

The BTG Sentry Bioconvertible IVC Filter is designed to provide immediate protection1 against Pulmonary Embolism (PE) in patients at transient risk of PE.

BTG Sentry

Unique Frame

  • Cylindrical Nitinol frame designed to minimize migration, perforation, embolization, and tilt
  • Self-expanding filter cone formed by 6 arms held centrally by a bioabsorbable filament2
  • Self-centering filtering cone is designed to reduce the risk of tilting and thereby maximizes filtration capacity

Bioconvertible Design

  • Designed to automatically bioconvert with arms retracting to the IVC wall after the period of transient risk (approximately 60 days)1, providing protection when you need it3-16
  • Bioconversion process leaves a patent lumen2
  • Eliminates the requirement, cost, and risk associated with IVC filter retrieval

Proven Results

  • The prospective multicenter SENTRY study demonstrated a high level of safety and effectiveness
  • The trial established 100% freedom from new symptomatic PEs through 12 months, while typical published rates of symptomatic PEs range from 0.5 – 6%17
  • Eliminates the requirement, cost, and risk associated with IVC filter retrieval

Click here for the BTG Sentry Clinical Data

BTG Sentry In-Service